epoetin beta + darbepoetin alfa

Epoetin beta + darbepoetin alfa refers to a treatment regimen or comparative study involving two distinct erythropoiesis-stimulating agents (ESAs). Epoetin beta (NeoRecormon) is a recombinant human erythropoietin with a relatively short half-life, typically requiring administration two to three times per week. Darbepoetin alfa (Aranesp) is a second-generation ESA with additional N-linked oligosaccharide chains, resulting in a significantly longer half-life and allowing for less frequent dosing, such as once weekly or every other week. Both drugs function as agonists of the erythropoietin receptor (EPOR) on erythroid progenitor cells in the bone marrow, stimulating their proliferation and differentiation into mature red blood cells. This specific combination entry is associated with a Phase 4 clinical trial (VAES) conducted by the Anemia Working Group Romania to compare the efficacy and stability of hemoglobin levels achieved by these two agents in hemodialysis patients.

Brand names

NeoRecormonAranesp

Other names

epoetinum betadarbepoetinumdarbepoetin alfaepoetin betaepoetinum beta + darbepoetinum-Anemia Working Group Romania-anemia